As part of a £10.5 million investment to life sciences, BioClavis have announced they will be creating a base in the Queen Elizabeth University Hospital in Glasgow. A research and development grant of £4.5million has been provided by Scottish Enterprise to the firm to work in collaboration with the NHS and university researchers. BioClavis is a spin-out from molecular profiling company BioSpyder. The grant money...
Innovate UK are providing an opportunity for small and medium sized enterprises to apply for a share of £15 million to support their innovative projects in the field of health and life sciences. Projects must show significant innovation in one of the priority areas: Increasing agricultural productivity Improving food quality and sustainability Advanced therapies (cell and gene therapies) Precision medicine Medicines discovery Preclinical technologies Advanced...
Working across Scotland with the Highlands and Islands Enterprise and in collaboration with partners, The Scottish Investment Bank (SIB) supports economic growth in Scotland by helping companies access finances and increases the supply of growth finance. The SIB have completed their annual review for 2016-2017 to understand the funding landscape. Below are some of the key figures from this years review. To read the full...
The Scottish Investment Bank have invested a record £63.5 million in to 146 Scottish Companies during 2016-2017. This is an increase of 23% from the year prior and demonstrates the SIB’s efforts to help meet the Scottish Government’s aim of increasing support to help companies raise and secure growth finance. To read the full article, click here.
NuCana, an Edinburgh-based medical firm has raised almost £75 million by floating on the stock market. NuCana develops techniques to boost the effectiveness of chemotherapy. The funds will be used to further clinical trials and expand the business in Edinburgh creating more jobs in the area. To read the full article, click here.
Exscientia Ltd received €15 million investment from Evotec AG giving them a minority stake. Exscientia is focused on Artificial Intelligence (AI) driven drug discovery and design. Evotec and Exscientia have worked in partnership since early 2016, the success of this relationship is the basis of this investment allowing further advances in their immuno-oncology therapeutic research in the future. To read the full article, click here.